POAI — Predictive Oncology Income Statement
0.000.00%
- $9.47m
- $8.73m
- $1.62m
Annual income statement for Predictive Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.25 | 1.42 | 1.51 | 1.63 | 1.62 |
Cost of Revenue | |||||
Gross Profit | 0.805 | 0.934 | 1 | 1.02 | 0.798 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 28.6 | 21.8 | 27.5 | 13.7 | 12.6 |
Operating Profit | -27.4 | -20.4 | -26 | -12.1 | -10.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -25.9 | -20.3 | -25.7 | -12 | -10.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -25.9 | -19.7 | -25.7 | -12 | -10.9 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -25.9 | -19.7 | -25.7 | -14 | -12.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -26.4 | -19.7 | -25.7 | -14 | -12.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -19.4 | -5.52 | -4.1 | -2.99 | -1.99 |